Although it is the most powerful predictor of early prostate cancer treatment-related complications and quality-of-life (QOL) outcomes, most studies do not stratify results by baseline function. Further, reporting functional outcomes as averaged numerical results may obscure informatively disparate courses. Using levels of treatment-related dysfunction, we address these problems and present the final QOL outcomes of our prospective cohort study of patients with early prostate cancer.
INTRODUCTION
The Institute of Medicine and the National Cancer Institute have identified quality of life in cancer survivors and "patient-centered communication" as priority research areas. 1, 2 These issues intersect in the more than 180,000 men annually diagnosed in the United States with clinically localized prostate cancer, nearly all probable long-term survivors, who must choose among treatment options that may profoundly affect their quality of life (QOL).
3 Although the three major treatment modalities, radical prostatectomy (RP), external-beam radiation therapy (EBRT) and brachytherapy (BT), have currently indistinguishable efficacy, 4-6 more than a decade of increasingly sophisticated QOL research has established their distinctive effects on urinary, bowel, and sexual function. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Results from these studies have become central to the counseling of patients as they incorporate QOL outcomes into choosing treatment.
Nevertheless, important clinical questions remain, yet incompletely answered by the prostate cancer QOL literature. Multiple studies have documented the dependence of long-term patient outcomes after localized prostate cancer treatment on baseline functional status. 8, 14, 17, 19, 20 Compromised pretreatment function may make patients more vulnerable to additional treatment-related dysfunction, whereas very advanced dysfunction (eg, severe erectile dysfunction) may leave little residual for additional treatment-related worsening. Although some studies highlight patients who are normal at baseline, especially for sexual function, few have examined the relationship between already compromised function and outcomes. More typically, prospective studies present both baseline and outcome QOL data as mean scale scores for entire cohorts, without any stratification by pretreatment status, instead representing treatment-related effects as average score changes. Averaged scores obscure individual patient courses, blending patients with varying amounts of pretreatment dysfunction who have improved, stable, or worsened function of varying magnitudes into one overall outcome. The numerical format itself may be problematic: although scale scores permit group comparisons and indicate the direction of functional change, interpreting purely numerical QOL data is challenging for patients and their physicians. [21] [22] [23] [24] This report addresses these issues.
On the basis of patient-reported distress from specific symptoms, we have translated responses to our validated instrument, the Prostate Cancer Symptom Indices (PCSI), into clinically defined functional levels of urinary, bowel, and sexual dysfunction, "normal," "intermediate," and "poor. '' 23 With this tool, we have stratified the 409 patients with localized prostate cancer in our prospective cohort study who received RP, EBRT, or BT by their baseline function and present their final (36-month) outcomes by their levels of function in addition to mean numerical score changes. In this article, we address two questions: (1) Does stratifying QOL analysis by baseline function identify qualitatively different outcomes between patients with different baseline sexual, urinary, and bowel function compared with data reported for the entire treatment cohorts? (2) Does presenting outcomes by level of function enrich the standard presentation, changes in mean scale scores?
METHODS

Patient Population and Data Collection
Patients with untreated localized prostate cancer seeking consultation at Massachusetts General Hospital, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Beth Israel-Deaconess Medical Center, or MetroWest Medical Center between 1994 and 2000 were invited to participate. We required that the baseline questionnaire be completed before treatment began, but not that treatment occur at the recruitment site. All hospital institutional review boards approved this study. We mailed follow-up questionnaires to 522 participating patients at 3, 12, 24, and 36 months after treatment began; follow-up was discontinued after 36 months. Excluding 84 patients who stopped participating before the 36-month questionnaire, 438 patients (84%) with complete follow-up comprised the study population. Patients who dropped out did not statistically significantly differ demographically, clinically, or in baseline QOL scores from those who did not. We report the results of 409 patients who chose the three most common treatment modalities: RP, EBRT, and BT.
We reviewed patient medical records to confirm demographic information, cancer stage, treatment received, and medical comorbidities scored according to the Index of Co-Existent Disease. 25 At least two urologists independently determined the surgical technique (nerve-sparing or not) of each RP patient on the basis of operative reports.
QOL Instruments
We measured urinary, sexual, and bowel function using our validated PCSI scales 26 Urinary, bowel, and sexual function scores were calculated as described previously.
26 Change scores were calculated by subtracting patients' baseline scores from the 36-month scores. Mean change scores were reported to be consistent with published literature, but we used the Kruskal-Wallis test to compare among different patient groups. To facilitate interpretability of results, we reported percentages of patients resulting in each functional level after treatment, but we evaluated comparisons between groups using the Kruskal-Wallis test. Analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary, NC); P Ͻ .05 denoted statistical significance. All reported P values are two-sided.
RESULTS
Baseline Patient Characteristics
Treatment groups included 127 patients who received RP, including 74 patients who received nerve-sparing surgery (NSRP) and 53 patients who received non-nerve-sparing surgery (NNSRP); 190 patients who received EBRT; and 92 patients who received BT. In general, study patients were socioeconomically advantaged, with 98% white, more than half with a college degree, and median income more than $40,000 (Table 1) . Patients who underwent RP, particularly NSRP, and patients who underwent BT were younger (P Ͻ .001) and had less comorbid disease (P Ͻ .003) than patients who underwent EBRT. Patients who underwent BT had lower-risk cancers than those in the other treatment groups (P Ͻ .001).
Quantitative QOL Outcomes at 36 Months Stratified by Baseline Functional Level
Analyzing QOL outcomes stratified by baseline function revealed that different levels of baseline sexual, bowel, and urinary function produced distinctive 36-month outcomes after localized prostate cancer treatments (Table 2 ; Appendix Figs A1 through A4, online only). Baseline Sexual Dysfunction and Urinary Obstruction/Irritation were prevalent, whereas far fewer patients had pretreatment Urinary Incontinence or Bowel Problems. In general, patients with normal baseline function, and thus greater potential for lost function, reported greater increases in dysfunction than those with preexisting dysfunction (intermediate or poor function).
However, all treatment modalities produced large increases in Sexual Dysfunction scores. The magnitude of impact of EBRT or surgical treatment on sexual function was similar for men who had normal or intermediate baseline function. Patients with poor baseline sexual function had little further increase of their already highly elevated dysfunction scores after any treatment. BT patients with normal baseline function seemed to preserve function better, compared with both similar patients receiving other treatments and patients who underwent BT with intermediate function.
Mean post-treatment changes in Bowel Problems scores were much smaller, although the modestly greater score increases in patients with normal versus intermediate baseline function were highly statistically significant. The increased 36-month Bowel Problems scores were clinically expected complications of EBRT and BT, but the clinical significance of the small, opposite mean changes after RP for patients with normal and intermediate baseline function is unclear, despite statistical significance. Too few patients had poor baseline bowel or urinary incontinence functions for analysis.
As expected, RP increased Urinary Incontinence more than EBRT and BT, but only for BT, with surprisingly large improvement among patients with intermediate function, were the differences between functional groups statistically significant.
Examining changes in Urinary Obstruction/Irritation scores revealed that patients with poor pretreatment dysfunction benefited from treatment. RP patients experienced the largest score decrease, followed by EBRT. For each treatment, score changes differed by pretreatment levels of function.
Qualitative QOL Outcomes at 36 Months Stratified by Baseline Functional Level
To expand the information represented by numerical score changes, we report outcomes expressed as functional levels, which indicates the proportion of patients with improved, preserved, or worsened function (Fig 1; Appendix Tables A2 through A5 , online only, display the same data in numerical format). For Sexual Dysfunction, the large increases in 36-month scores in patients with normal or intermediate baseline function translate into large majorities of patients whose functional level decreased after treatment. Although treatment-related dysfunction increased progressively less after surgery, EBRT, and BT, normal and intermediate baseline function produced similar proportions of patients with diminished function: 94% and 91%, respectively, after NNSRP; 92% and 93%, respectively, after -10  10  7  15  18  1  Clinical stage, percent  T1  76  72  82  75  79  T2  24  28  18  25  21  Risk category, percent  Low  34  36  30  35  57  Intermediate  34  34  33  32  22  High  33  30  38  34  22 Abbreviations: RP, radical prostatectomy; NSRP, nerve-sparing radical prostatectomy; NNSRP, non-nerve-sparing radical prostatectomy; EBRT, external-beam radiation therapy; BT, brachytherapy; PSA, prostate-specific antigen.
NSRP; 74% and 72%, respectively, after EBRT; and 54% and 62%, respectively, after BT. The greater treatment-related dysfunction after surgery translates into fewer patients who retain an ability to have sexual intercourse (good or intermediate function) at 36 months. Among patients with normal baseline function, one third after NSRP or NNSRP retained some useful function, compared with half of patients who underwent EBRT and four fifths of patients after BT (P Ͻ .001). For those with intermediate baseline function, less than 10% after RP preserved an ability to have sexual intercourse, compared with 29% after EBRT and 38% after BT (P ϭ .08). Patients with poor baseline sexual function fared dismally after all treatments (P ϭ .25).
Functional outcomes for Bowel Problems also differed by treatment modality and patient baseline function, although the most important contrast was between patients undergoing radiation treatments, who lost function, and surgery patients, who did not. For patients with normal baseline function, two thirds worsened after EBRT or BT, almost all to intermediate function. In contrast, the 27% of patients who underwent RP with normal baseline function who worsened was offset by a similar proportion (32%) of those with baseline intermediate function who improved. However, patients who underwent EBRT and BT with intermediate baseline function, whose average score changes at 36 months were small, were as likely to improve as worsen.
For Urinary Incontinence, worsened functional outcomes were almost completely confined to patients with complete urinary control at baseline (normal). Incontinence developed in more than twice as many surgical patients as EBRT or BT patients at 36 months (P Ͻ .001), but almost all had intermediate, not poor, function, even after surgery. A trend suggested that NSRP better preserved function compared with NNSRP (P ϭ .11). For patients with intermediate baseline function, at least as many improved after treatment as worsened.
Although improvement of Urinary Obstruction/Irritation was evident at 36 months after all treatments, it was especially common after surgery, including 55% of patients with intermediate baseline function and 70% of men with poor function, half of whom had normal 36-month function. For radiation patients with intermediate function, improvements outnumbered declines in function, but for patients with poor function, 53% improved after EBRT and 62% after BT.
DISCUSSION
For patients trying to factor QOL into their treatment decisions, the primary questions are "What happens after each treatment to patients like me?" and "How do the changes affect them?" The typical format of QOL reports, grouped data and averaged numerical scale changes, answer these questions incompletely. In this report, we present the final outcomes of 409 prospectively studied patients stratified by their baseline function, the most powerful predictor of QOL outcomes, and report their outcomes both in the typical numerical format and also as the proportion of patients with normal, intermediate, and poor function. These results provide insights unavailable from prior reports. Our results demonstrate that the impact of RP, EBRT, and BT on 36-month sexual, bowel, and urinary function differs depending on patients' baseline levels of function. Prior studies have documented that RP causes urinary incontinence, radiation treatments (EBRT and BT) cause bowel problems and short-term urinary obstruction/irritation, and all three treatment modalities cause sexual dysfunction. 29 However, these global associations may obscure importantly divergent trends for patients with different levels of baseline function. For example, patients with normal function could be plausibly expected to have either more or less treatment-related dysfunction: more, because greater current function increases the potential for loss, or less, because of greater resilience (increased physiologic reserve allowing better recovery of lost function over time). Our stratified analysis provides evidence that the former mechanism prevails: patients with normal baseline function generally have the largest treatment-related increases in dysfunction scores from baseline to 36 months, compared with patients with intermediate or poor baseline function. In contrast to reporting one global outcome for each treatment modality, stratified results quantify the outcome differences among patients with different levels of pretreatment function, making possible counseling to patients about treatment-related dysfunction to patients more similar to them.
Examining patients with poor baseline function also produced noteworthy, otherwise obscured observations. We documented the frequent treatment-related benefit in patients with poor function measured by the Urinary Obstruction/Irritation scale. The results confirm our clinical suspicion that the previously reported improvement in urinary obstruction/irritation after surgery is primarily driven by patients with poor baseline function, and also that EBRT and BT may also lead to small improvements for such patients, presumably because of a radiation-caused reduction in prostate size. In contrast, patients with normal baseline function worsened after all treatments. Grouped data and average numerical score changes conceal these disparate outcomes. Some clinically unexpected results, such as worsened bowel dysfunction after surgery and improved urinary incontinence after radiation, have also been previously reported by others.
7,11
These findings require further investigation and may indicate that regression to the mean, a consequence of grouped quantitative data, is occurring.
We found one other prospective study in the literature examining patient outcomes stratified by "normal" or "lower" baseline function 7, 8 ; baseline QOL status was ascertained by patient recall at 6 months, and analysis omitted nerve-sparing RP and brachytherapy. Our use of three functional levels rather than two may have allowed additional observations, including the large treatment-related increase in sexual dysfunction scores for patients with intermediate baseline function. Because patients with poor baseline function experience a "ceiling effect," with little potential for additional treatmentrelated functional worsening, including them in averaged scores may underestimate the treatment effects experienced by patients with normal or intermediate function.
In addition, we are not the first to recognize the need to improve the clinical interpretability of numerical QOL data. [21] [22] [23] [24] Presenting outcomes using functional levels is one potentially useful approach.
Although not as precise as numerical scores, changes in functional levels have easily identifiable clinical meaning: moving from normal to intermediate function signifies the onset of noticeably distressing symptoms, and moving from intermediate to poor signifies meaningfully worsened dysfunction. Functional levels may improve over the standard numerical report of QOL outcomes in three ways. First, they allow stratification of patients by pretreatment function, the most influential factor predicting outcome, using clinically meaningful categories. It enables researchers to make stratified comparisons of treatment modalities, directly addressing confounding by treatment that, for example, broadly disfavors patients who undergo EBRT because of their poorer pretreatment characteristics. Second, it parses treatment outcomes as the likelihood of having worsened, preserved, or improved function and indicates the level of impairment, rather than as changes in mean scale scores, to which clinical meaning must be attached. For example, in patients with normal baseline function, RP led to a 56-point increase in the Sexual Dysfunction score, or, alternatively, only 36% to 37% of patients preserving useful function (sufficient erectile function for intercourse). Third, this approach both illuminates small but statistically significant changes of unclear clinical significance and indicates the limits of the impact of larger ones. The modest but highly statistically significant differences in Bowel Problems scores for surgical versus radiation patients did not meet the strict 10-point statistical definition of clinical significance 10, 11, 30, 31 ; however, patients who underwent RP were twice as likely to preserve normal function than those who underwent either radiation treatment and were much less likely to have poor function.
Our findings may help improve the counseling of patients about the QOL impact of localized prostate cancer treatments. Using stratified results, physicians could provide a patient information more individualized to his circumstances on the basis of his baseline functional status, about the impact of RP, EBRT, and BT on sexual, bowel, and urinary function. The description of outcomes using proportions of patients with improved, maintained, or worsened function (Fig 1; Appendix Tables A2 through A5) may be an additional approach to translate research findings, usually reported as score changes ranging from 0 to 100, for patient counseling.
This study has several potential limitations. Our study's source of data, including its observational design, single geographic sample, and underrepresentation of nonwhite patients, reduces its generalizability. We had few patients with poor baseline function for either Urinary Incontinence or Bowel Problems, preventing useful analysis. In addition, other boundaries for "good," "intermediate," and "poor" function are possible, which could potentially influence results. We used a definition that incorporates patient-reported distress, a widely accepted modifier of functional status, and preserves the comprehensive scope of multi-item scales, which are more robust than single-item measures for QOL outcomes. 20, 22, 23, 30, 32, 33 The mean functional and distress scores among patients within the resultant normal, intermediate, and poor levels in each domain were widely separated and significantly different. However, although our finding that patient baseline function significantly influences the magnitude of treatmentrelated dysfunction is supported by previous literature, 8, 14, 17, 19, 20 further studies examining stratified outcomes are needed to confirm our results. We performed a sensitivity analysis, reanalyzing our data using a different definition (with intermediate function representing patients with only one to two symptoms, whereas poor function included all patients with three or more symptoms or any very distressful symptom), and did not find significantly altered results.
